BUZZ-<a href="https://laohu8.com/S/ATRA">Atara Biotherapeutics</a> sinks as FDA rejects cancer drug application** Shares of drugmaker Atara Biotherapeutics ATRA.O fall 49% to $6.91 premarket
** Co says U.S. FDA has rejected its application to market Ebvallo, a treatment for a rare and aggressive cancer linked to the Epstein-Barr virus in patients who have received organ transplants
** FDA said main trial was insufficient to prove effectiveness; had earlier indicated single-arm trial was acceptable - ATRA
** No safety or manufacturing concerns raised, co says; plans meeting with FDA to discuss next steps
** Epstein-Barr virus is a common virus that can cause infections and, in rare cases, lead to certain cancers
** As of last close, stock up ~36% over the past year
(Reporting by Sahil Pandey in Bengaluru)
((Sahil.Pandey@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.